Related Experiment Videos
Lipid Research Clinics Coronary Primary Prevention Trial: results and implications
Insights
Lowering cholesterol with cholestyramine significantly reduced coronary heart disease (CHD) risk by 19% in men with high LDL cholesterol. This cholesterol-lowering therapy is vital for preventing CHD events in high-risk individuals.
Area of Science:
- Cardiovascular Medicine
- Preventive Cardiology
- Clinical Trials
Background:
- Primary hypercholesterolemia poses a significant risk for coronary heart disease (CHD).
- Effective strategies for lowering cholesterol are crucial for CHD prevention in at-risk populations.
Purpose of the Study:
- To evaluate the efficacy of cholestyramine in reducing cholesterol levels and CHD risk.
- To assess the impact of cholesterol reduction on CHD morbidity and mortality.
Main Methods:
- The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) involved 3,806 asymptomatic men with primary hypercholesterolemia.
- Participants were randomized to receive cholestyramine or a placebo.
- Key endpoints included definite CHD events, myocardial infarction, and all-cause mortality.
Main Results:
- Cholestyramine treatment led to significant reductions in total cholesterol (8.5%) and LDL cholesterol (12.6%).
- A 19% reduction in the risk of definite CHD events (including death and nonfatal myocardial infarction) was observed in the cholestyramine group (p < 0.05).
- Significant decreases in angina, positive exercise tests, and need for coronary bypass surgery were also noted.
Conclusions:
- Lowering LDL cholesterol levels through cholestyramine therapy effectively diminishes CHD morbidity and mortality in high-risk men.
- The findings underscore the importance of cholesterol-lowering interventions for clinical and public health strategies in CHD prevention.
Abstract:
The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) tested the efficacy of lowering cholesterol levels in reducing the risk of coronary heart disease (CHD) in 3,806 asymptomatic, middle-aged men with primary hypercholesterolemia. The group treated with cholestyramine had 8.5% and 12.6% greater reductions in total and low-density lipoprotein levels, respectively, than those achieved in the placebo group. The cholestyramine group had a 19% reduction in risk (p less than 0.05) of the primary endpoint of definite CHD, death or definite nonfatal myocardial infarction. Corresponding and significant reductions were also seen for angina, development of a positive exercise test, and coronary bypass surgery. All-cause mortality was only slightly, and not significantly, reduced in the cholestyramine group, reflecting more violent and accidental deaths in the cholestyramine subjects. When the cholestyramine group was analyzed separately, a 19% reduction in CHD risk was also associated with each decrement of 8% in the total cholesterol level. Moreover, CHD incidence in men in whom a decrease of 25% in total cholesterol was sustained, a typical response to the prescribed dosage (24 g/day) of cholestyramine resin, was half that of men who remained at the pretreatment level. The LRC-CPPT findings show that reducing the total cholesterol level by lowering the LDL cholesterol level can diminish the incidence of CHD morbidity and mortality in men at high risk for CHD because of increased LDL cholesterol levels. These results have considerable importance for the prevention of CHD through cholesterol lowering, at both the clinical and public health levels.